Sound Income Strategies LLC Purchases 387,027 Shares of Perrigo Company plc $PRGO

Sound Income Strategies LLC raised its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 34.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,525,384 shares of the company’s stock after buying an additional 387,027 shares during the period. Sound Income Strategies LLC owned about 1.11% of Perrigo worth $16,779,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Geneos Wealth Management Inc. lifted its stake in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares during the last quarter. Kestra Investment Management LLC grew its position in Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after acquiring an additional 642 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after acquiring an additional 1,014 shares during the last quarter. UMB Bank n.a. increased its stake in Perrigo by 161.5% in the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after purchasing an additional 1,213 shares during the period. Finally, Meeder Asset Management Inc. purchased a new stake in Perrigo in the fourth quarter worth $28,000. Institutional investors own 95.91% of the company’s stock.

Wall Street Analyst Weigh In

PRGO has been the subject of a number of recent analyst reports. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $19.33.

Perrigo Stock Up 6.7%

Shares of NYSE PRGO opened at $11.01 on Friday. Perrigo Company plc has a 52-week low of $9.23 and a 52-week high of $28.43. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -0.84, a PEG ratio of 1.22 and a beta of 0.51. The stock has a 50 day moving average price of $10.90 and a 200 day moving average price of $12.13. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The company had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.Perrigo’s quarterly revenue was down 7.2% on a year-over-year basis. During the same period last year, the business posted $0.60 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts expect that Perrigo Company plc will post 2.11 earnings per share for the current year.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were paid a dividend of $0.29 per share. The ex-dividend date was Friday, May 29th. This represents a $1.16 annualized dividend and a dividend yield of 10.5%. Perrigo’s dividend payout ratio (DPR) is currently -8.85%.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.